Lorne Golub, DMD, SUNY Distinguished Professor of Oral Biology & Pathology at Stony Brook University School of Dental Medicine, has been named a recipient of the 2018 William J. Gies Award for Vision, Innovation and Achievement.
The prestigious Gies Awards, named after legendary dentist and biochemist William J. Gies, Ph.D., honor individuals and organizations that exemplify the highest standards in oral health and dental education, research and leadership.
Dr. Golub was honored in the category of “Innovation – Dental Educator.”
Golub is an innovator in the development of medicines to promote oral health and to treat chronic inflammatory diseases, has been named a Fellow of the National Academy of Inventors (NAI).
Dr. Golub’s research innovations and patents are largely related to his discoveries and development of therapeutic medications as inhibitors of tissue-destructive enzymes called the matrix metalloproteinases (MMPs). These novel medications have shown evidence of efficacy in a variety of oral and systemic diseases including periodontitis, dermatitis, arthritis, diabetes, cancer, and cardiovascular and lung diseases. His discoveries serve as a model for dental and medical research focusing on novel multiple-action drug molecules which can inhibit both tissue-destructive enzymes (MMPs), and inflammatory mediators, produced by diseased human and animal tissues.
A faculty member in the School of Dental Medicine since 1973, Dr. Golub holds 55 United States patents and 104 international patents. The drug Periostat® (based on his seminal patents filed in 1983 and later) resulted from his work which developed novel non-antibiotic formulations and compositions of tetracyclines as inhibitors of MMPs and inflammatory mediators. Periostat® is used by clinicians internationally as a systemic adjunct for the treatment of chronic inflammatory, and bone-destructive periodontal disease. Another drug, Oracea®, also resulted from his research on non-antibiotic tetracyclines as inhibitors of inflammatory mediators, and is used to treat chronic inflammatory skin disease. Most recently, he has been developing and patenting (with a Stony Brook Professor of Chemistry and Pharmacological Sciences) newer MMP-inhibitor drugs which are not based on the tetracycline molecule.
Add comment